ResMed Inc (RMD)
Gross profit margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 2,939,167 | 2,854,336 | 2,749,995 | 2,632,836 | 2,545,957 | 2,482,132 | 2,414,913 | 2,355,663 | 2,260,783 | 2,134,228 | 2,058,831 | 2,024,310 | 1,992,500 | 1,948,561 | 1,906,726 | 1,839,098 | 1,797,774 | 1,800,178 | 1,764,825 | 1,731,219 |
Revenue (ttm) | US$ in thousands | 5,021,540 | 4,926,780 | 4,807,490 | 4,546,017 | 4,444,877 | 4,364,797 | 4,235,737 | 4,222,994 | 4,015,671 | 3,763,271 | 3,624,405 | 3,578,126 | 3,539,492 | 3,443,759 | 3,348,896 | 3,196,825 | 3,091,065 | 3,091,753 | 3,027,899 | 2,957,011 |
Gross profit margin | 58.53% | 57.94% | 57.20% | 57.92% | 57.28% | 56.87% | 57.01% | 55.78% | 56.30% | 56.71% | 56.80% | 56.57% | 56.29% | 56.58% | 56.94% | 57.53% | 58.16% | 58.23% | 58.29% | 58.55% |
March 31, 2025 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $2,939,167K ÷ $5,021,540K
= 58.53%
The gross profit margin of ResMed Inc. has displayed a generally stable trend over the specified period, with fluctuations within a narrow range. Starting from approximately 58.55% as of June 30, 2020, the margin experienced slight declines throughout the subsequent quarters, reaching a low point of approximately 55.78% on June 30, 2023. This declining trajectory persisted despite minor recoveries, such as the marginal increase to 57.01% on September 30, 2023.
In recent periods, there has been a modest upward trend, culminating in a gross profit margin of approximately 57.94% as of December 31, 2024, and further rising to roughly 58.53% by March 31, 2025. The overall pattern indicates resilience in gross profitability with subtle downward pressure over the long term, followed by a gradual recovery in the most recent quarters.
The observed fluctuations suggest that while ResMed has maintained a relatively high gross profit margin, there have been some variations possibly attributable to changes in cost structure, product mix, or pricing strategies. The short-term dips and subsequent recoveries reflect typical industry dynamics and internal operational factors. Overall, the gross profit margin remains indicative of a profitable company's ability to control production costs relative to revenue, with a cautiously optimistic outlook based on the recent upward movement.
Peer comparison
Mar 31, 2025